Verve Therapeutics Inc (VERV)
6.35
+0.31
(+5.13%)
USD |
NASDAQ |
Nov 05, 16:00
6.35
0.00 (0.00%)
After-Hours: 16:08
Verve Therapeutics Revenue (Quarterly): 6.692M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 6.692M |
| March 31, 2024 | 5.695M |
| December 31, 2023 | 5.144M |
| September 30, 2023 | 3.117M |
| Date | Value |
|---|---|
| June 30, 2023 | 2.093M |
| March 31, 2023 | 1.404M |
| December 31, 2022 | 1.012M |
| September 30, 2022 | 0.929M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.929M
Minimum
Sep 2022
6.692M
Maximum
Jun 2024
3.261M
Average
2.605M
Median
Revenue (Quarterly) Benchmarks
| Ardelyx Inc | 98.24M |
| Biomarin Pharmaceutical Inc | 745.74M |
| Sage Therapeutics Inc | 11.87M |
| ALX Oncology Holdings Inc | -- |
| Immuneering Corp | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -49.80M |
| Total Expenses (Quarterly) | 65.53M |
| EPS Diluted (Quarterly) | -0.59 |
| Enterprise Value | -64.82M |
| Profit Margin (Quarterly) | -744.2% |
| Earnings Yield | -40.79% |
| Normalized Earnings Yield | -40.79 |